Some research has linked the human papillomavirus vaccination (HPV) to the development of multiple sclerosis (MS), but a recent study in Scandinavia shows this isn’t the case.
The findings, published in Tuesday's issue of JAMA, found that girls and women ages 10 to 44 who received the HPV vaccination in Sweden and Denmark had no increased risk for MS or other central nervous system disorders.
Nikolai Madrid Scheller, of the Statens Serum Institut in Copenhagen, and colleagues conducted the study between 2006 and 2013.
A total of 3,983,824 girls and women were eligible for inclusion in the study group. Of those, 789,082 were vaccinated during the study period with a total of 1,927,581 quadrivalent human papillomavirus (qHPV) vaccine doses. During the follow-up process, 4,322 MS cases and 3,300 cases of other central nervous system diseases were discovered, but the researchers determined that the qHPV vaccine was not the cause.
It is not known if the onset of the central nervous system disorders after HPV vaccination truly reflects the background rates in females or represents a true increased risk.
"Our study adds to the body of data that support a favorable overall safety profile of the qHPV vaccine and expands on this knowledge by providing comprehensive analyses of multiple sclerosis and other demyelinating diseases,” the authors said in the JAMA article. “The size of the study and the use of nationwide registry data of unselected populations from Denmark and Sweden allowed adequately powered analyses that are likely generalizable.
Since the approval and licensure of the qHPV vaccine in 2006, and the subsequent approval and licensure of the bivalent HPV vaccine, more than 175 million doses have been distributed globally.
"These findings do not support concerns about a causal relationship between qHPV vaccination and demyelinating diseases."